Adial Pharmaceuticals Inc... (ADIL)
0.75
-0.04 (-4.46%)
At close: Mar 03, 2025, 3:59 PM
0.73
-2.19%
After-hours: Mar 03, 2025, 05:32 PM EST
No 1D chart data available
| Bid | 0.72 |
| Market Cap | 4.84M |
| Revenue (ttm) | 35.78K |
| Net Income (ttm) | -14.48M |
| EPS (ttm) | -2.94 |
| PE Ratio (ttm) | -0.25 |
| Forward PE | -0.59 |
| Analyst | Buy |
| Ask | 0.73 |
| Volume | 131,539 |
| Avg. Volume (20D) | 885,774 |
| Open | 0.76 |
| Previous Close | 0.79 |
| Day's Range | 0.73 - 0.79 |
| 52-Week Range | 0.72 - 3.60 |
| Beta | 1.18 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 27, 2018
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ADIL
Website https://www.adialpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADIL stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 970.38% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
6 days ago
+20.64%
Adial Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
3 months ago
+15.04%
Adial Pharmaceuticals shares are trading higher after the company announced results from its AD04-103 pharmacokinetics study for AD04, aimed at treating alcohol use disorder.
